Mechanisms of endothelial dysfunction in the metabolic syndrome

被引:104
作者
Prakash C. Deedwania
机构
[1] Division of Cardiology, Department of Medicine, Univ. of CA at San Francisco Program, Fresno, CA 93703
关键词
Nitric Oxide; Metabolic Syndrome; Hyperglycemia; Therapeutic Lifestyle Change; Diabetic Dyslipidemia;
D O I
10.1007/s11892-003-0019-8
中图分类号
学科分类号
摘要
Cardiovascular disease is a leading cause of death and disability in patients with diabetes or metabolic syndrome (MS). The available data suggest that many patients with diabetes or MS already have vascular abnormalities by the time they are diagnosed with their metabolic disorder. Endothelial dysfunction (ED), which is one of the initial steps in the process of vascular disease, is often present in patients with diabetes or MS. Adthough the precise mechanism(s) by which diabetes or MS causes ED remains to be elucidated, several possibilities exist. Hyperglycemia, hyperinsulinemia, increased oxidative stress, and diabetic dyslipidemia can all contribute to ED individually or in concert with one another. ED in the setting of diabetes or MS can subsequently result in the activation of a variety of pathways that alter vascular function and participate in the process of vascular remodeling and atherosclerosis. Because insulin resistance is the predominant mechanism responsible for various perturbations seen in MS or diabetes, it is essential to develop a therapeutic strategy that can improve insulin sensitivity with the hope that such interventions would reduce the risk of future cardiovascular events. Copyright © 2003 by Current Science Inc.
引用
收藏
页码:289 / 292
页数:3
相关论文
共 33 条
[1]  
Donnelly R., Emslie-Smith A.M., Gardner I.D., Morris A.D., ABC of arterial and venous disease. Vascular complications of diabetes, BMJ, 320, pp. 1062-1066, (2000)
[2]  
Ray N.F., Thamer M., Gardner E., Chan J., Economic consequences of diabetes mellitus in the U.S. in 1997, Diabetes Care, 21, pp. 296-309, (1998)
[3]  
Wilson P., Kannel W., Hyperglycemia, Diabetes, and Vascular Disease, (1992)
[4]  
Stamler J., Vaccaro O., Neaton J.D., Wentworth D., Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial, Diabetes Care, 16, pp. 434-444, (1993)
[5]  
Haffner S.M., Lehto S., Ronnemaa T., Et al., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N. Engl. J. Med., 339, pp. 229-234, (1998)
[6]  
Lakka H.M., Laaksonen D.E., Lakka T.A., Et al., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, JAMA, 288, pp. 2709-2716, (2002)
[7]  
Deedwania P.C., The deadly quartet revised, Am. J. Med., 105, (1998)
[8]  
Fagan T.C., Deedwania P.C., The cardiovascular dysmetabolic syndrome, Am. J. Med., 105, (1998)
[9]  
Pyorala M., Miettinin H., Laakso M., Pyorala K., Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men. The 22-year follow-up results of the Helsinki Policemen Study, Circulation, 98, pp. 398-404, (1998)
[10]  
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, pp. 2486-2497, (2001)